Clinical trial
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom…
NCT00099619 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00099619 |
|---|---|
| Title | Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy |
| Official title | Efficacy of Exenatide Compared With Insulin Glargine in Patients With Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide/insulin glargine, insulin glargine/exenatide |
| Enrollment | 138 |
| Start date | Sep 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Dec 20, 2004 |
| Last update posted | Feb 23, 2015 |
| Countries | Australia, Greece, Hungary, Italy, Mexico, Poland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: